Visit https://www.peervoice.com/FTR860 to view the entire programme with slides. After completing “John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes”, participants will be able to: Summarize the complications, burden, and unmet needs associated with the diagnosis and management of hypercortisolism; Describe the mechanistic rationale associated with new and emerging therapies in hypercortisolism; Recall safety and efficacy data relating to new and emerging treatment strategies in patients with hypercortisolism; and Appraise recent data regarding newer therapies in the context of current approaches to the management of difficult-to-treat metabolic disease.

Visit https://www.peervoice.com/HPJ860 to view the entire programme with slides. After completing “David Cherney, MD, PhD / Abhinav Sharma, MD, PhD - Optimizing Cardio-Kidney Protection in Patients With T2D and CKD: Expert Insights on the Evolving Role of GLP-1 RAs”, participants will be able to: Examine the pathogenic mechanisms underlying chronic kidney disease (CKD) and type 2 diabetes (T2D), and their relevance to the foundational pillars of cardio-kidney protection; Discuss the latest clinical evidence on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in providing cardio-kidney protection for patients with CKD and T2D; and Identify strategies to optimize cardio-kidney outcomes in patients with CKD and T2D.

Visit https://www.peervoice.com/BJJ860 to view the entire programme with slides. After completing “Francesco Cappelli, MD, PhD - Meaningful Data From Madrid: Expanding Our Understanding of Phase 3s and OLEs in ATTR-CM”, participants will be able to: Identify the impact of disease-modifying therapies on accepted markers of transthyretin amyloid cardiomyopathy (ATTR-CM) disease severity, including NT-proBNP, 6MWD, and NAC stage in phase 3 trial populations; and Evaluate recently presented outcomes from post-hoc analyses and open-label extensions of phase 3 trials in ATTR-CM in the context of previously published and presented outcomes across the landscape of disease-modifying therapies.

Visit https://www.peervoice.com/STJ860 to view the entire programme with slides. After completing “Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence”, participants will be able to: Improved knowledge of current efficacy data from clinical trials of novel treatments for familial chylomicronemia syndrome (FCS); and Improved knowledge of the safety profiles of emerging treatments for FCS, based on clinical trial outcomes.

Visit https://www.peervoice.com/GWG860 to view the entire programme with slides. After completing “Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lung Cancer”, participants will be able to: Recognise the perspectives and concerns of patients with locally advanced, unresectable EGFR-mutated NSCLC in evaluating treatment decisions; Apply practical approaches to facilitate patient understanding of the rationale, implications, and benefits of curative intent treatment strategies in the management of locally advanced, unresectable EGFR-mutated NSCLC; and Implement practical communication approaches to support patients with locally advanced, EGFR-mutated NSCLC in making decisions about treatment.

Visit https://www.peervoice.com/VBS860 to view the entire programme with slides. After completing “Nicoletta Policek, PhD - When You Are Not an HIV Specialist But You Are Addressing Broader Healthcare Needs of Individuals With HIV: What Do You Need to Know?”, participants will be able to: Identify strategies to improve communication between people living with HIV (PWLH) and healthcare providers (HCPs), reduce HCP stigma, and build positive perceptions of health management by non-HIV specialist HCPs; and Propose key practical preventative steps for HIV-associated comorbidities.

Visit https://www.peervoice.com/RUF860 to view the entire programme with slides. After completing “Yves Robitaille, MD, CSPQ, DABOM - Cardiovascular Risk Management in Patients Living With Obesity: Applying the Latest Evidence to Practice”, participants will be able to: Describe the association between obesity and the risk of cardiovascular disease (CVD); Evaluate the latest clinical evidence of various therapeutic options, including GLP-1 receptor agonists, in patients living with obesity and CVD; Discuss comprehensive treatment strategies to improve cardiovascular risk in patients living with obesity, incorporating both pharmacologic and non-pharmacologic approaches; and Formulate individualized approaches to manage side effects associated with different therapeutic options and improve their uptake in suitable patients.

Visit https://www.peervoice.com/CNZ860 to view the entire programme with slides. After completing “Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care”, participants will be able to: Recognise the role, strengths, and limitations of real-world evidence in guiding decision-making related to stroke prevention in patients with atrial fibrillation (AF); Evaluate available real-world data studies related to the use of oral anticoagulants for stroke prevention in AF, including in special populations; and Propose patient-specific oral anticoagulation plans for stroke prevention in AF based on not only clinical trials, but also real-world evidence.

Visit https://www.peervoice.com/MWF860 to view the entire programme with slides. After completing “Geneviève Matte, MDCM, FRCPC - Improving Early Diagnosis of hATTR Amyloidosis: A Critical Step Towards Better Outcomes”, participants will be able to: Describe current challenges in the diagnosis of hereditary transthyretin (hATTR) amyloidosis; Outline key manifestations that should prompt screening for hATTR amyloidosis; and Discuss expert recommendations to facilitate diagnosis, including key assessments to help identify patients with hATTR amyloidosis earlier.

Visit https://www.peervoice.com/KHV860 to view the entire programme with slides. After completing “Isabel Conceição, MD - Prioritizing Patient-Centered Care for ATTR: Expert Perspectives on the Evolution of Data and Decision-Making”, participants will be able to: Identify best practices to optimize the recognition and diagnosis of patients with transthyretin amyloidosis (ATTR), including those with ATTRv-PN and those with mixed phenotype ATTR; Evaluate current and emerging treatment options for hereditary ATTR with polyneuropathy (ATTRv-PN), including key differences between therapies with regards to clinical trial design, patient populations studied, available outcomes, and administration considerations; and Apply a comprehensive, patient-centered approach to management of patients with ATTR, including those with ATTRv-PN and those with mixed phenotype ATTR.

Visit https://www.peervoice.com/RHA860 to view the entire programme with slides. After completing “Phyllis C. Zee, MD, PhD - Sleep, Heart, Brain: What Promotes and How to Reduce Cardiovascular Risk in Patients With Narcolepsy”, participants will be able to: Describe the pathophysiology of narcolepsy in the context of cardiovascular (CV) effects; Differentiate between narcolepsy medications regarding their impact on CV risk factors; Identify medications used for common comorbidities associated with narcolepsy that have the potential to increase CV risk; and Propose strategies to manage CV risk in patients with narcolepsy.

Visit https://www.peervoice.com/DRF860 to view the entire programme with slides. After completing “Michael Thorpy, MD - When Sleep Is Exhausting: Improving Diagnosis and Outcomes in Patients With Idiopathic Hypersomnia”, participants will be able to: Recognize health risks associated with idiopathic hypersomnia; Differentiate idiopathic hypersomnia from other conditions that cause excessive daytime sleepiness (EDS); Explain how to establish a confirmatory diagnosis of idiopathic hypersomnia; and Propose effective, individualized, evidence-based management strategies for patients with idiopathic hypersomnia.

Visit https://www.peervoice.com/QHY860 to view the entire programme with slides. After completing “Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC”, participants will be able to: A key challenge is that physicians cannot simply order a “MET test”; different tests must be used to detect the different alterations;; Exon 14 skipping mutations, amplification, and fusion can be detected via DNA or RNA-based next-generation sequencing (NGS);; Amplification and fusion may also be detected by fluorescence in situ hybridization (FISH);; and Overexpression is detected via immunohistochemistry (IHC)..

Visit https://www.peervoice.com/UPK860 to view the entire programme with slides. After completing “Jeffrey Habert, MD, CCFP, FCFP - Steps Towards Earlier Detection of Lung Cancer: Harnessing the Power of Primary Care”, participants will be able to: Explain the rationale for screening asymptomatic patients for lung cancer based on identified eligibility criteria; Outline practical tips for primary care to screen and monitor appropriate patients for lung cancer, in order to facilitate early identification; Discuss when to investigate lung cancer in symptomatic patients; and Apply effective strategies to optimize referral into the diagnostic assessment clinic.

Visit https://www.peervoice.com/HPP860 to view the entire programme with slides. After completing “Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC”, participants will be able to: Differentiate between pathophysiology of MET alterations in patients with NSCLC and the recommended strategies for their detection; Apply best practices to overcome challenges in the identification of patients with NSCLC and MET vulnerabilities; and Summarize current and emerging strategies for targeting MET alterations as a therapeutic vulnerability in patients with NSCLC.

Visit https://www.peervoice.com/RVW860 to view the entire programme with slides. After completing “Simon Couillard, MD, MSc - Improving Outcomes in Severe Eosinophilic Asthma: Translating Recent Evidence With Biologics Into Patient Care”, participants will be able to: Discuss the pathogenic mechanisms in severe eosinophilic asthma and the role of biomarkers in informing treatment; Describe the role of biologics in improving patient outcomes and their impact on background medication use; and Outline the most recent real-world evidence with biologics for severe eosinophilic asthma and its clinical implications for patient management.

Visit https://www.peervoice.com/GFE860 to view the entire programme with slides. After completing “Geoffrey Liu, MD, MSc, FRCPC, FISPE - Optimizing the Potential for Patients With ALK-Positive mNSCLC Throughout Their Treatment Journey”, participants will be able to: Discuss the importance of first-line treatment and the factors to consider when selecting a treatment strategy for patients with ALK-positive metastatic non–small-cell lung cancer (mNSCLC); Describe the evolving clinical evidence and guideline recommendations for the treatment of ALK-positive mNSCLC; Review the toxicities of the new generation tyrosine kinase inhibitors (TKIs) used as first-line in the treatment of ALK-positive mNSCLC; and Apply key learnings and strategies to enhance the toxicity management of new generation TKIs for optimal patient outcomes.

Visit https://www.peervoice.com/UET860 to view the entire programme with slides. After completing “Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023”, participants will be able to: Discuss emerging clinical data related to the management of hypertrophic cardiomyopathy (HCM); Describe the latest updates on guideline recommendations for provision of evidence-based care for patients with HCM; and Use emerging clinical data and latest updates on guideline recommendations to manage patients with HCM.

Visit https://www.peervoice.com/XVK860 to view the entire programme with slides. After completing “Rosalyn Juergens, MD, PhD - Why Precision Matters in NSCLC: Challenges and Solutions for Targeting Rare Oncogenic Driver Mutations in the Canadian Landscape”, participants will be able to: Discuss the rationale for timely comprehensive genomic profiling in patients with advanced non-small–cell lung cancer (NSCLC); Review expert recommendations to optimize genomic testing in the Canadian healthcare setting; Describe guideline recommendations for the treatment of patients with advanced NSCLC and rare oncogenic driver alterations; and Evaluate the latest evidence with targeted therapies for advanced NSCLC harbouring rare oncogenic driver alterations, with a focus on RET alterations.

Visit https://www.peervoice.com/RHS860 to view the entire programme with slides. After completing “Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations”, participants will be able to: Identify current and anticipated strategies for managing NSCLC without actionable oncogenic driver mutations, including combination approaches with immunotherapies and other agents; and Assess the clinical relevance of safety and efficacy data from randomized clinical trials evaluating novel treatment approaches in advanced NSCLC without actionable genomic alterations.